Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc. (CARM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
carm · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Carisma Therapeutics, Inc. (CARM) measures how much investors pay for each dollar of the company's trailing earnings. CARM's current PE ratio of 0.00x is calculated by dividing its stock price of $0.00 by its TTM earnings per share of $0.19. −100.0% discount vs 5Y avg 21.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2011 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Carisma Therapeutics, Inc.You CARM | $0M | 0.00x | — | $0.19 |
 Aspire Biopharma Holdings, Inc. ASBP | $1M | N/A | — | -$16.38 |
 CDT Equity Inc. CDT | $4M | N/A | — | -$1177.90 |
 Enveric Biosciences, Inc. ENVB | $1M | N/A | — | -$36.24 |
 Indaptus Therapeutics, Inc. INDP | $4M | N/A | — | -$21.58 |
 Jasper Therapeutics, Inc. JSPR | $7M | N/A | — | -$3.95 |
 Onconetix, Inc. ONCO | $0M | N/A | — | -$4.28 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-1.46 | — | |
2023-12-31 FY2023 | — | $-2.59 | — | |
2022-12-31 FY2022 | — | $-1.52 | — | |
2021-12-31 FY2021 | — | $-0.04 | — | |
2020-12-31 FY2020 | — | $-4.80 | — | |
2019-12-31 FY2019 | — | $-23.65 | — | |
2018-12-31 FY2018 | — | $-10.91 | — | |
2017-12-31 FY2017 | — | $-22.24 | — | |
2016-12-31 FY2016 | 21.29x | $1.79 | — | |
2015-12-31 FY2015 | — | $-35.23 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Carisma Therapeutics, Inc. (CARM) measures how much investors pay for each dollar of the company's trailing earnings. CARM's current PE ratio of 0.00x is calculated by dividing its stock price of $0.00 by its TTM earnings per share of $0.19.
Frequently asked questions
CARM pe ratio · 6 questionsCARM's current PE ratio is 0.00x as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of $0.19. Data sourced from Financial Modeling Prep via CARM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Carisma Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09